Published in J Clin Invest on January 04, 2011
A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol (2012) 2.47
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses (2011) 1.30
RIG-I like receptors in antiviral immunity and therapeutic applications. Viruses (2011) 0.99
Myeloid dendritic cells in HIV-1 infection. Curr Opin HIV AIDS (2011) 0.86
Expression of A20 is reduced in pancreatic cancer tissues. J Mol Histol (2012) 0.84
Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology (2012) 0.83
Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C. Immunology (2014) 0.83
USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity. Mol Cancer (2014) 0.80
Epigenetic Regulation of Antibody Responses by the Histone H2A Deubiquitinase MYSM1. Sci Rep (2015) 0.79
Increased A20 mRNA Level in Peripheral Blood Mononuclear Cells is Associated With Immune Phases of Patients With Chronic Hepatitis B. Medicine (Baltimore) (2015) 0.77
Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs. Gene Ther (2011) 0.76
Is A20 a suitable target to enhance dendritic cell antigen presentation? Immunotherapy (2011) 0.75
An effective vaccination approach augments anti-HIV systemic and vaginal immunity in mice with decreased HIV-1 susceptible α4β7high CD4+ T cells. Curr HIV Res (2013) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol (2004) 26.12
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 14.43
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell (1999) 12.50
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 12.41
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science (2000) 10.98
Retinoic acid imprints gut-homing specificity on T cells. Immunity (2004) 9.76
The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol (2004) 9.42
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature (2003) 7.56
Homing and cellular traffic in lymph nodes. Nat Rev Immunol (2003) 7.23
Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell (1993) 7.10
T-cell function and migration. Two sides of the same coin. N Engl J Med (2000) 6.47
Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med (1999) 6.09
Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science (2006) 6.06
CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity (2004) 5.48
Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol (2003) 5.46
Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science (2006) 5.31
ELAM-1 is an adhesion molecule for skin-homing T cells. Nature (1991) 5.12
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63
Mucosal vaccines: the promise and the challenge. Nat Rev Immunol (2006) 4.41
Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med (2007) 4.20
Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med (2002) 4.18
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14
Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med (2003) 3.74
Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med (2003) 3.48
The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem (1990) 3.41
Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood (2003) 3.40
Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem (1992) 3.36
Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. Eur J Biochem (2000) 3.23
CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J Immunol (2006) 3.04
Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J Exp Med (2005) 3.02
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med (2004) 2.64
CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J Clin Invest (2002) 2.63
The role of beta7 integrins in CD8 T cell trafficking during an antiviral immune response. J Exp Med (1999) 2.62
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol (2006) 2.57
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
CCR7 expression and memory T cell diversity in humans. J Immunol (2001) 2.42
Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol (2004) 2.41
Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A (1998) 2.33
Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J Biol Chem (2005) 2.27
The rational design of an AIDS vaccine. Cell (2006) 2.11
Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem (1995) 2.05
Progress toward an HIV vaccine. Annu Rev Med (2005) 1.78
CD4+ T cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest (2001) 1.76
A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med (2008) 1.65
Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol (2006) 1.63
A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol (2005) 1.63
Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol (2003) 1.41
Migration and differentiation of CD8+ T cells. Immunol Rev (2002) 1.41
CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest (2005) 1.33
Identification of a novel class of retinoic acid receptor beta-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J Biol Chem (1999) 1.22
P-selectin and P-selectin glycoprotein ligand 1 are major determinants for Th1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J Exp Med (2003) 1.15
An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med (2006) 1.15
Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J Immunol (2009) 1.12
Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine. J Immunol (2004) 1.05
Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine (2006) 1.00
Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res (2004) 0.98
Defining carbohydrate antigens as HIV vaccine candidates. Curr Pharm Des (2007) 0.91
Immune mechanisms associated with protection from vaginal SIV challenge in rhesus monkeys infected with virulence-attenuated SHIV 89.6. J Med Primatol (2005) 0.80
Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol (2004) 2.41
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology (2014) 2.04
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest (2005) 1.75
A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med (2008) 1.65
Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity (2011) 1.63
CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther (2005) 1.51
Stable knockdown of estrogen receptor alpha by vector-based RNA interference suppresses proliferation and enhances apoptosis in breast cancer cells. Cancer Biol Ther (2006) 1.44
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther (2011) 1.32
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res (2002) 1.23
HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology (2011) 1.22
Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther (2013) 1.20
An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med (2006) 1.15
Twist-2 controls myeloid lineage development and function. PLoS Biol (2008) 1.10
The endoplasmic reticulum chaperone protein GRP94 is required for maintaining hematopoietic stem cell interactions with the adult bone marrow niche. PLoS One (2011) 1.07
Ontogeny of proteolytic immunity: IgM serine proteases. J Biol Chem (2004) 1.07
Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res (2002) 1.05
CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther (2010) 1.05
Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther (2004) 1.03
The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation. Blood (2013) 0.99
A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res (2003) 0.98
Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res (2004) 0.98
Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother (2009) 0.97
IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol (2010) 0.97
Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther (2009) 0.95
Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res (2003) 0.95
Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res (2003) 0.95
Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells (2009) 0.94
Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology (2007) 0.94
Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. J Immunother (2013) 0.94
A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther (2010) 0.92
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev (2008) 0.92
Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther (2006) 0.92
Intrabody and intrakine strategies for molecular therapy. Mol Ther (2003) 0.91
A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS One (2010) 0.91
Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother (2003) 0.91
HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. Arch Biochem Biophys (2010) 0.90
Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res (2007) 0.90
Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods (2003) 0.89
Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells. Cancer Res (2009) 0.89
Lentiviral transduction of human dendritic cells. Methods Mol Biol (2004) 0.89
Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy (2012) 0.88
Identification of a MHC class-II restricted epitope in carcinoembryonic antigen. Cancer Immunol Immunother (2003) 0.88
Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J Biol Chem (2004) 0.85
A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J Immunol (2004) 0.85
Enhanced intracellular stability of sFv-Fc fusion intrabodies. Methods (2004) 0.84
Epigenetic control of natural killer cell maturation by histone H2A deubiquitinase, MYSM1. Proc Natl Acad Sci U S A (2013) 0.84
Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res (2003) 0.83
Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treat Rev (2012) 0.83
Dendritic cell-based tumor vaccines and antigen presentation attenuators. Mol Ther (2006) 0.82
Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies. J Immunol Methods (2002) 0.82
A super TLR agonist to improve efficacy of dendritic cell vaccine in induction of anti-HCV immunity. PLoS One (2012) 0.80
Anti-tumor immune responses following neoadjuvant immunotherapy with a recombinant adenovirus expressing HSP72 to rodent tumors. Cancer Immunol Immunother (2005) 0.80
A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity. Vaccine (2009) 0.80
HER2-targeting recombinant protein with truncated pseudomonas exotoxin A translocation domain efficiently kills breast cancer cells. Cancer Biol Ther (2008) 0.80
Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. FASEB J (2003) 0.80
Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence. Clin Cancer Res (2010) 0.79
SOCS1 silencing can break high-dose dendritic cell immunotherapy-induced immune tolerance. Mol Med Rep (2011) 0.78
A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response. PLoS One (2012) 0.78
[Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating]. Ai Zheng (2006) 0.78
Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. Cancer Lett (2009) 0.78
SOCS1 downregulation in dendritic cells promotes memory T-cell responses. Vaccine (2007) 0.77
Enhanced generation of myeloid lineages in hematopoietic differentiation from embryonic stem cells by silencing transcriptional repressor Twist-2. Cloning Stem Cells (2009) 0.77
The effect of direct translocation across endosomes on the cytotoxicity of the recombinant protein e23sFv-Fdt-casp6 to HER2 positive gastric cancer cells. Biomaterials (2011) 0.77
Suppressor of cytokine signaling 1 inhibition strategy to enhance anti-HIV vaccination. Expert Rev Vaccines (2006) 0.76
Cloning of apoB intrabodies: specific knockdown of apoB in HepG2 cells. Biochem Biophys Res Commun (2008) 0.76
Inhibition of antigen-presentation attenuators to augment vaccines. Curr Opin Mol Ther (2006) 0.76